Clinical Trials Arena on MSN4d
PDS Biotechnology commences trial for head and neck squamous cell carcinomaPDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...
A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery. It was a Friday afternoon, ...
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.
About Esophageal Squamous Cell Carcinoma (ESCC) Globally ... Dosage interruption of TEVIMBRA in the TEVIMBRA plus chemotherapy arm due to an adverse drug reaction occurred in 49% of patients.
The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with ...
for pembrolizumab (Keytruda ®) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback